ARV Guidelines

Table 24c. Drug Interactions Between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents) This table provides information on the known or predicted interactions between nucleoside reverse transcriptase inhibitors (NRTIs) and non-antiretroviral drugs. Recommendations for managing a particular drug interaction may differ depending on whether a new antiretroviral (ARV) drug is being initiated in …

NRTI interactions Read More »

AU Comment: rilpivirine (RPV) Despite there being no direct effect on RPV plasma concentration, high doses of oral supplements may modify gastric pH, thereby affecting RPV absorption – subsequent potential impact on maintenance of viral suppression. AU Comment: Between-class ARV switching in the context of between-class ARV switches, clinicians may need to factor in enzyme …

NNRTI interactions Read More »

Table 24a. Drug Interactions Between Protease Inhibitors and Other Drugs This table provides information on the known or predicted interactions between protease inhibitors (PIs) and non-antiretroviral (ARV) drugs. When information is available, interactions for boosted atazanavir (ATV) (with either ritonavir [RTV] or cobicistat [COBI]) and unboosted ATV are listed separately. The term “all PIs” refers …

PI Drug interactions Read More »

AU Comment: Additional PK data and resources ARVs requiring specific acidity (e.g. ATV and RPV) may also be affected by the physiological effects of oral supplementation – variable concentration-specific effects of supplementation on gastric pH and absorption of ARVs cannot be excluded as having interaction potential RTV is also an inducer of glucuronosyl transferase (UDP-GT). …

Overview Read More »

This section has information on Drug-Drug Interactions. Please click on the below links or follow the table of contents to access the information you are looking for. Overview NNRTI interactions INSTI interactions HIV-1 gp120-Directed Attachment Inhibitors Interactions between INSTI & NNRTI or PI PI Drug interactions NRTI interactions CCR5 Antagonist Drug Interactions Interactions between PIs …

Drug-Drug Interactions Read More »

AU Comment: Cost considerations and ART in the Australian context The Australian Government provides fully subsidised ARV drugs under the Highly Specialised Drugs (HSD) Program. To gain access to a Commonwealth funded drug under this program, a patient must be an Australian resident in Australia (or other eligible person) and have a Medicare card. Patients …

Cost Considerations and ART Read More »

AU Comment: Weight gain and INSTIs Several reports have identified associations between the use of integrase strand transfer inhibitors (INSTIs) and increased weight and/or body mass index (BMI). It is unclear if this is a causal relationship or is associated with increased morbidity from conditions typically associated with increased weight such as type 2 diabetes …

Adverse Effects of ARV Agents Read More »

AU Comment: Australian data on rates of virological suppression Data from the 2022 Annual Surveillance Report estimates at the end of 2021, there were 29 460 people living with HIV in Australia. Of these an estimated 91% (26 830) had been diagnosed. Of those diagnosed at the end of 2021, an estimated 96% (25 820) …

Adherence to the Continuum of Care Read More »

This section has information on Limitations to Treatment Safety & Efficacy. Please click on the below links or follow the table of contents to access the information you are looking for. Cost Considerations and ART Adherence to the Continuum of Care Adverse Effects of ARV Agents

AU Comment: Timing of ART commencement in OIs Data on when to commence ART in HIV patients with an opportunistic infection (OI) are mostly derived from studies undertaken in resource-limited countries where medical care and patient follow-up may be different to Australia. In general, ART should be commenced within 2 weeks of commencing treatment for …

TB/HIV Read More »